Eyenovia, Inc. (NASDAQ:EYEN – Get Free Report) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 249,400 shares, an increase of 346.2% from the January 31st total of 55,900 shares. Based on an average daily volume of 366,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 12.1% of the shares of the company are sold short.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Eyenovia in a report on Thursday, February 6th. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. Finally, LADENBURG THALM/SH SH reissued a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th.
Get Our Latest Research Report on EYEN
Institutional Trading of Eyenovia
Eyenovia Stock Down 1.7 %
Shares of NASDAQ EYEN opened at $1.69 on Friday. The stock has a market cap of $2.35 million, a PE ratio of -0.03 and a beta of 1.24. The business has a fifty day moving average of $4.91 and a two-hundred day moving average of $22.82. Eyenovia has a 52-week low of $1.43 and a 52-week high of $205.60. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74.
About Eyenovia
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Recommended Stories
- Five stocks we like better than Eyenovia
- Do ETFs Pay Dividends? What You Need to Know
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.